Eupraxia Pharmaceuticals (EPRX) Price & Analysis

Compare

32 Followers

EPRX Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$3.07 - C$8.13

Previous CloseN/A

Volume2.50K

Average Volume (3M)23.74K

Market Cap

C$268.36M

Enterprise ValueC$295.74M

Total Cash (Recent Filing)C$27.45M

Total Debt (Recent Filing)C$52.77K

Price to Earnings (P/E)―

Beta0.72

Next Earnings

Nov 05, 2025

EPS Estimate

-0.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding35,849,354

10 Day Avg. Volume20,356

30 Day Avg. Volume23,736

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$14.34

Price Target Upside94.31% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical Trial OutcomesThe company's commentary around early results on safety and efficacy of Cohort 8 in the Phase 2a portion of the RESOLVE study was very positive and supports the potential for EP-104GI.

Drug DevelopmentEP-104GI demonstrated a favorable safety profile, with plasma fluticasone levels remaining low and consistent, and no serious adverse events reported.

Market PotentialEupraxia has the potential for a best-in-class treatment for the ever-growing eosinophilic esophagitis (EoE) market, and has shown the potential for an annual treatment of EP-104GI in this condition, which could grow to a ~1M addressable patient market.

Bears Say

Cash Flow ConcernsCash at June 30, 2025, was $19.8M. The company expects its cash balance, combined with anticipated proceeds from the exercise of in-the-money warrants, to fund operations into Q3 2026.

Financial PerformanceFor Q2 2025, Eupraxia reported a net loss of $8.7M versus $6.1M in Q2 2024, driven by higher R&D and G&A expenses.

Eupraxia Pharmaceuticals News

Celldex data supports positive Eupraxia thesis, says H.C. Wainwright

H.C. Wainwright believes Celldex’s (CLDX) Phase 2 data for barzolvolimab in patients with eosinophilic esophagitis supports the positive...

3h ago

CLDX

EPRX

Eupraxia Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Eupraxia Pharmaceuticals (EPRX) with an Overweight rating and $11 price target Published first...

27d ago

EPRX

Eupraxia Pharmaceuticals’ EP-104GI: A Promising Comprehensive Treatment for Eosinophilic Esophagitis with Strong Buy Recommendation

Analyst Brandon Folkes of H.C. Wainwright maintained a Buy rating on Eupraxia Pharmaceuticals, retaining the price target of...

3h ago

EPRX

Eupraxia Pharmaceuticals: Promising Potential in EoE Treatment with EP-104GI and Strong Financial Position

Brandon Folkes, an analyst from H.C. Wainwright, reiterated the Buy rating on Eupraxia Pharmaceuticals. The associated price target...

7d ago

EPRX

Eupraxia Pharmaceuticals Advances EoE Treatment Trials Amid Financial Challenges

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an announcement. Eupraxia Pharmaceuticals announced the dosing of the first patient...

8d ago

EPRX

Eupraxia Pharmaceuticals to Present at Key Investor Conferences

The latest announcement is out from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ). Eupraxia Pharmaceuticals announced its participation in several...

29d ago

EPRX

Promising Developments in Eupraxia Pharmaceuticals’ EoE Trial Justify Buy Rating

H.C. Wainwright analyst Brandon Folkes maintained a Buy rating on Eupraxia Pharmaceuticals today and set a price target...

1M ago

EPRX

Eupraxia Pharmaceuticals Advances RESOLVE Trial with First Patient Dosed in Phase 2b

The latest announcement is out from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ). On July 8, 2025, Eupraxia Pharmaceuticals announced...

1M ago

EPRX

Eupraxia Pharma doses first patient in Phase 2b trial of EP-104GI in esophagitis

Eupraxia Pharmaceuticals (EPRX) announced the first patient dosed in the Phase 2b randomized, placebo-controlled portion of the RESOLVE...

1M ago

EPRX

Promising Future for Eupraxia Pharmaceuticals: Buy Rating Affirmed on Strong EP-104GI Trial Results

Brandon Folkes, an analyst from H.C. Wainwright, has initiated a new Buy rating on Eupraxia Pharmaceuticals (EPRX). Brandon...

2M ago

EPRX

Eupraxia Pharmaceuticals initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy rating and $12 price target Eupraxia has...

2M ago

EPRX

Eupraxia Pharmaceuticals initiated with a Speculative Buy at Canaccord

Canaccord initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Speculative Buy rating and C$9 price target In May...

2M ago

EPRX

Eupraxia Pharmaceuticals Strengthens Governance with Board Elections and Strategic Approvals

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an announcement. Eupraxia Pharmaceuticals announced the successful election of its board...

3M ago

EPRX

Eupraxia Pharmaceuticals to Host Virtual Event on EoE Treatment Study

An update from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) is now available. On May 7, 2025, Eupraxia Pharmaceuticals announced...

3M ago

EPRX

EPRX FAQ

What was Eupraxia Pharmaceuticals’s price range in the past 12 months?

Eupraxia Pharmaceuticals lowest stock price was C$3.07 and its highest was C$8.13 in the past 12 months.

What is Eupraxia Pharmaceuticals’s market cap?

Eupraxia Pharmaceuticals’s market cap is C$268.36M.

When is Eupraxia Pharmaceuticals’s upcoming earnings report date?

Eupraxia Pharmaceuticals’s upcoming earnings report date is Nov 05, 2025 which is in 77 days.

How were Eupraxia Pharmaceuticals’s earnings last quarter?

Eupraxia Pharmaceuticals released its earnings results on Aug 12, 2025. The company reported -C$0.333 earnings per share for the quarter, missing the consensus estimate of -C$0.256 by -C$0.077.

Is Eupraxia Pharmaceuticals overvalued?

According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Eupraxia Pharmaceuticals pay dividends?

Eupraxia Pharmaceuticals does not currently pay dividends.

What is Eupraxia Pharmaceuticals’s EPS estimate?

Eupraxia Pharmaceuticals’s EPS estimate is -0.29.

How many shares outstanding does Eupraxia Pharmaceuticals have?

Eupraxia Pharmaceuticals has 35,849,354 shares outstanding.

What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?

Eupraxia Pharmaceuticals reported an EPS of -C$0.333 in its last earnings report, missing expectations of -C$0.256. Following the earnings report the stock price went up 0.537%.

Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?

Currently, no hedge funds are holding shares in TSE:EPRX

Eupraxia Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-158.24%

Trailing 12-Months

Asset Growth

-5.79%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals (EPRX) is a clinical-stage biotechnology company focused on developing innovative drug products for the treatment of chronic diseases. The company's primary focus is on creating long-acting formulations that aim to provide sustained therapeutic effects, particularly in areas with significant unmet medical needs such as osteoarthritis and other pain-related conditions. Eupraxia's lead product candidate is EP-104IAR, a proprietary sustained-release formulation intended to alleviate pain and improve joint function in patients with osteoarthritis.

Eupraxia Pharmaceuticals (EPRX) Earnings & Revenues

Historic Earnings Reports

EPRX Stock 12 Month Forecast

Average Price Target

C$14.34

▲(94.31% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"C$3","10":"C$10","17":"C$17","6.5":"C$6.5","13.5":"C$13.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16.57788288,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$16.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$14.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6.5,10,13.5,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.32,8.032144836923077,8.744289673846154,9.456434510769231,10.168579347692308,10.880724184615385,11.592869021538462,12.305013858461539,13.017158695384616,13.729303532307693,14.44144836923077,15.153593206153847,15.865738043076924,{"y":16.57788288,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.32,7.86,8.4,8.94,9.48,10.02,10.559999999999999,11.1,11.64,12.18,12.719999999999999,13.26,13.799999999999999,{"y":14.34,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.32,7.44923076923077,7.578461538461538,7.707692307692308,7.836923076923077,7.966153846153846,8.095384615384615,8.224615384615385,8.353846153846154,8.483076923076924,8.612307692307692,8.741538461538461,8.87076923076923,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.96,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.27,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.51,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >